

Title (en)  
METHOD FOR TREATING CANCER

Title (de)  
KREBSBEHANDLUNGSVERFAHREN

Title (fr)  
METHODE DE TRAITEMENT DU CANCER

Publication  
**EP 1351677 A4 20090819 (EN)**

Application  
**EP 02720788 A 20020111**

Priority  
• US 0200943 W 20020111  
• US 26312701 P 20010119

Abstract (en)  
[origin: WO02056755A2] A method of treating patients with cancer that involves administration of a combination regimen of a platinum agent, a taxane agent, and a formula (I) toxicity-reducing agent. The preferred order of administration is the formula (I) compound, followed by the platinum complex, followed by the taxane agent.

IPC 1-7  
**A61K 31/335**; **A61K 31/105**; **A61K 33/24**; **A61K 31/663**; **A61K 31/185**; **A61P 35/00**

IPC 8 full level  
**A61K 31/185** (2006.01); **A61K 31/282** (2006.01); **A61K 31/337** (2006.01); **A61K 31/555** (2006.01); **A61K 31/663** (2006.01); **A61K 33/243** (2019.01); **A61P 31/00** (2006.01); **A61P 35/00** (2006.01); **A61P 39/02** (2006.01); **A61P 43/00** (2006.01)

CPC (source: EP US)  
**A61K 31/185** (2013.01 - EP); **A61K 31/337** (2013.01 - EP); **A61K 31/555** (2013.01 - EP); **A61K 31/663** (2013.01 - EP); **A61K 33/243** (2018.12 - EP US); **A61P 31/00** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **A61P 39/02** (2017.12 - EP); **A61P 43/00** (2017.12 - EP)

Citation (search report)  
• [DA] US 5919816 A 19990706 - HAUSHEER FREDERICK H [US], et al  
• [A] WO 9811898 A1 19980326 - BIONUMERIK PHARMACEUTICALS INC [US], et al  
• [X] SCHWARTZ GN, SCHILSKY RL ET AL: "Phase I Trial of Escalating Doses of BNP7787 in Patients Receiving Paclitaxel (TAX) and Cisplatin (CDDP)", PROC AM SOC CLIN ONCOL, vol. 19, 2000, pages 218A, XP002534844, Retrieved from the Internet <URL:http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst\_detail\_view&confID=2&abstractID=100040> [retrieved on 20090701]  
• [X] SCHILSKY R, SCHWARTZ G ET AL: "Phase I Trial of Escalating Doses of BNP7787 in Patients Receiving Cisplatin (CDDP) and Paclitaxel (TAX)", ASCO ANNUAL MEETING, 1999, XP002534845, Retrieved from the Internet <URL:http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst\_detail\_view&confID=17&abstractID=14900> [retrieved on 20090701]  
• [Y] CAVALLETTI E ET AL: "Oral and intravenous BNP7787 protects against paclitaxel-mediated neurotoxicity in Wistar rats", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 40, March 1999 (1999-03-01), & 90TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; PHILADELPHIA, PENNSYLVANIA, USA; APRIL 10-14, 1999, pages 398, XP001537150, ISSN: 0197-016X  
• [Y] HAUSHEER FREDERICK H ET AL: "BNP7787: A novel chemoprotecting agent for platinum and taxane toxicity", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 41, March 2000 (2000-03-01), & 91ST ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; SAN FRANCISCO, CALIFORNIA, USA; APRIL 01-05, 2000, pages 769 - 770, XP001537151, ISSN: 0197-016X  
• [Y] HAUSHEER F ET AL: "BNP7787: A novel antitumor potentiating drug which protects against cisplatin and carboplatin toxicities", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, NEW YORK, NY, vol. 38, 1 March 1997 (1997-03-01), pages 311, XP002052163, ISSN: 0197-016X  
• [A] DORR R T: "A REVIEW OF THE MODULATION OF CISPLATIN TOXICITIES BY CHEMOPROTECTANTS", CANCER CHEMOTHERAPY REPORTS, XX, XX, 1 January 1995 (1995-01-01), pages 131 - 154, XP000885450  
• [A] ZANETTA G ET AL: "Neoadjuvant chemotherapy with cisplatin, ifosfamide and paclitaxel for locally advanced squamous-cell cervical cancer", ANNALS OF ONCOLOGY 199809 NL, vol. 9, no. 9, September 1998 (1998-09-01), pages 977 - 980, XP002534846, ISSN: 0923-7534  
• [A] BOISDRON-CELLE MICHELE ET AL: "Platinum compounds-taxanes pharmacologic interactions", BULLETIN DU CANCER, EDITIONS SCIENTIFIQUES ELSEVIER, PARIS, FR, vol. 87, no. numero special, 1 August 2000 (2000-08-01), pages 30 - 33, XP009119107, ISSN: 0007-4551  
• See references of WO 02056755A2

Citation (examination)  
• CHABNER, B.A. AND LONGO, D.L.: "Cancer Chemotherapy and Biotherapy- Principles and Practice, Second Edition", 1996, LIPPINCOTT-RAVEN PUBLISHING, pages: 285  
• ROWINSKY ERIC K ET AL: "Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristine", JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol. 119, no. 12, 1993, pages 727 - 733, ISSN: 0171-5216  
• PARKER R J ET AL: "Taxol effect on cisplatin sensitivity and cisplatin cellular accumulation in human ovarian cancer cells.", JOURNAL OF THE NATIONAL CANCER INSTITUTE. MONOGRAPHS 1993 LNKD- PUBMED:7912534, no. 15, 1993, pages 83 - 88, ISSN: 1052-6773  
• ZAFFARONI N ET AL: "Induction of apoptosis by taxol and cisplatin and effect on cell-related proteins in cisplatin-sensitive and -resistant human ovarian cancer cells", BRITISH JOURNAL OF CANCER, vol. 77, no. 9, May 1998 (1998-05-01), pages 1378 - 1385, ISSN: 0007-0920  
• LIEBMANN J E ET AL: "Sequence dependence of paclitaxel (Taxol) combined with cisplatin or alkylators in human cancer cells.", ONCOLOGY RESEARCH 1994 LNKD- PUBMED:7919549, vol. 6, no. 1, 1994, pages 25 - 31, ISSN: 0965-0407  
• JEKUNEN A P ET AL: "Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro", BRITISH JOURNAL OF CANCER, vol. 69, no. 2, 1994, pages 299 - 306, ISSN: 0007-0920

Designated contracting state (EPC)  
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

DOCDB simple family (publication)  
**WO 02056755 A2 20020725**; **WO 02056755 A3 20020926**; AU 2002251763 B2 20060504; CA 2434270 A1 20020725; EP 1351677 A2 20031015; EP 1351677 A4 20090819; JP 2004523518 A 20040805; JP 2009292837 A 20091217; MX PA03006359 A 20040420

DOCDB simple family (application)

**US 0200943 W 20020111**; AU 2002251763 A 20020111; CA 2434270 A 20020111; EP 02720788 A 20020111; JP 2002557269 A 20020111;  
JP 2009212441 A 20090914; MX PA03006359 A 20020111